close

GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic, wfor the treatment of various cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, it is developing TherAtoh, a preclinical program involving the delivery of the human atonal gene for the production of therapeutic proteins by cells in the inner ear. Further, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases, including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and HSV-2. It has strategic alliances and research contracts with the U.S. department of homeland security, the U.S. department of agriculture, PATHÂ’S malaria vaccine initiative, the U.S. naval medical research center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The company was founded in 1992 and is based in Gaithersburg, Maryland.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	2.57
Volume	7141
Volume Avg	25448
52 Week High	5.31
52 Week Low	2.00
PE	N/A
PE (group average)	39
EPS Year	-0.46
EPS change Q/Q	-112.5%
EPS change Q/Q Yr ago	-56.41%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-119.74%
REV change Q/Q	1.92%
REV change Q/Q Yr ago	82.76%
EPS next Q est	0.00
EPS next Y est	-0.82
Divident Annual	0.00
Dividend Yield	0%